Biopharm Drug Dispos. 1992 Mar;13(2):95-103.
Methimazole increases the plasma concentrations of the albendazole metabolites of netobimin in sheep.

Lanusse CE, Prichard RK.

Institute of Parasitology, McGill University, Macdonald College, Ste-Anne de Bellevue, PQ, Canada.

The influence of methimazole (MTZ) on the pharmacokinetics of netobimin (NTB) and its metabolites was investigated in adult sheep. NTB zwitterion suspension was administered at 20 mg kg-1 by intraruminal injection either alone or with simultaneous administration of MTZ intramuscularly at 1.5 mg kg-1. Blood samples were taken serially over a 120-h period and plasma was analysed by HPLC for NTB, albendazole (ABZ), albendazole sulphoxide (ABZSO), and albendazole sulphone (ABZSO2). NTB parent drug showed fast absorption, low area under the plasma concentration-time curve (AUC) and was rapidly removed from plasma after both treatments. The presence of MTZ did increase significantly the ABZ AUC (138 per cent) and mean residence time (MRT) (86 per cent). Concomitant treatment with MTZ resulted in a notably higher ABZSO plasma profile with significantly longer elimination half-life (t1/2 beta) (390 per cent) and MRT (252 per cent) and with significantly higher AUC (95 per cent). Also, MTZ induced significant increases in ABZSO2 t1/2 beta, AUC, and MRT. We have demonstrated a pharmacokinetic interaction between MTZ and NTB metabolites. MTZ may alter the liver biotransformation of ABZ metabolites which results in pronounced changes in the disposition kinetics of anthelmintically active metabolites.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1550912&dopt=Abstract albendazole Albenza




Infection. 1992 Jan-Feb;20(1):19-24.
Experience in the chemotherapy of severe, inoperable echinococcosis in man.

Todorov T, Vutova K, Mechkov G, Tonchev Z, Georgiev P, Lazarova I.

Institute of Pharmacology, Medical Academy, Sofia, Bulgaria.

The effect of albendazole and mebendazole was studied in 25 patients with severe, multiple, inoperable echinococcosis. Eleven patients were treated with albendazole 10 mg/kg/day for four courses of 30 days with 15-day drug-free intervals and 14 with mebendazole 50-70 mg/kg/day continuously for between 6 and 24 months. The determination of cyst response was based on the changes in cyst appearance as seen by radiography, ultrasound and computed tomography. Albendazole and mebendazole were found to have favourable effects in patients with severe, inoperable hydatid disease, although the degree of response varied. Treatment with albendazole was successful in seven cases, partially successful in two, and failure was noted in the other two patients. In patients treated with mebendazole, success was established in three, partial success in five and failure in six cases. The differences in response were mainly associated with cyst condition and the drug used. In some cases long-term therapy and retreatment should be recommended.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1563807&dopt=Abstract albendazole Albenza




Arch Neurol. 1992 May;49(5):535-8.
Albendazole therapy for giant subarachnoid cysticerci.

Del Brutto OH, Sotelo J, Aguirre R, Diaz-Calderon E, Alarcon TA.

Neurologic Service, Regional Hospital of Ecuadorian Institute of Social Security of Guayaquil.

Albendazole is considered to be the drug of choice for treatment of parenchymal brain cysticercosis. Its efficacy, however, for treatment of subarachnoid cysticerci has not been established, to our knowledge. In this study, we treated four patients who had giant subarachnoid cysticerci with albendazole at daily doses of 15 mg/kg of body weight for 8 days. Computed tomographic studies showed that all cysts disappeared 3 months after the end of treatment. This was associated with marked clinical improvement in every case. Our results indicated that albendazole is highly effective for treatment of this form of the disease.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1580817&dopt=Abstract albendazole Albenza




Comp Biochem Physiol C. 1991;100(3):397-400.
Comparative study on gastric absorption of albendazole and mebendazole in rats.

Prieto JG, Justel A, del Estal JL, Barrio JP, Alvarez AI.

Laboratory Animal Physiology, University of Leon, Spain.

1. A study was carried out to determine the kinetics of the gastric absorption of two wide spectrum benzimidazole anthelmintics, albendazole and mebendazole. 2. The method used was gastric recirculation of solutions containing the drugs in concentrations ranging from 0.5 to 100 mM. 3. The results obtained showed that absorption corresponds to first order kinetics, with diffusion constants of 0.0087 min-1 for albendazole and 0.0077 min-1 for mebendazole. 4. Blood levels of the drugs for the whole range of concentrations were always higher in the case of albendazole.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1687533&dopt=Abstract albendazole Albenza




J Parasitol. 1992 Feb;78(1):125-6.
Effects of albendazole on Gnathostoma spinigerum in mice.

Maleewong W, Loahabhan P, Wongkham C, Intapan P, Morakote N, Khamboonruang C.

Department of Parasitology, Faculty of Medicine, Khon Kaen University, Thailand.

Mice were infected with 5 advanced third-stage larvae of Gnathostoma spinigerum and, beginning on the 28th day postinfection, were treated orally with albendazole. In the first experiment, infected mice each received albendazole once a day (30, 60, or 90 mg/kg/day) for 21 consecutive days. In the second experiment, they received albendazole twice a day (30 and 30, 60 and 60, or 90 and 90 mg/kg/day) for the same length of time. All mice were killed 28 days after cessation of treatment and the carcasses were examined for parasites. With both regimens, the administration of albendazole significantly reduced the number of larvae. However, a complete larvicidal effect was obtained only with albendazole at the dosage of 90 mg/kg twice daily.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1738054&dopt=Abstract albendazole Albenza




J Clin Pharmacol. 1992 Jan;32(1):28-31.
Clinical pharmacokinetics of albendazole in patients with brain cysticercosis.

Jung H, Hurtado M, Sanchez M, Medina MT, Sotelo J.

Laboratory of Neuropharmacology, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.

Albendazole pharmacokinetics were studied in eight patients who were receiving albendazole in doses of 15 mg/kg per day for 8 days as treatment of brain cysticercosis. Albendazole was not detected in plasma, but its main metabolite albendazole sulphoxide could be measured. Maximum plasma levels for albendazole sulphoxide ranged from 0.45 to 2.96 micrograms/mL. The half-life of albendazole sulphoxide was between 10 and 15 hours. A double peak was found in three patients. Mean residence time values were from 14 to 20 hours. Plasma levels of albendazole sulphoxide at the steady state showed great intraindividual variability. The results suggest that albendazole can be administered twice daily rather than three times as is currently done.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1740534&dopt=Abstract albendazole Albenza




Med Parazitol (Mosk). 1991 Sep-Oct(5):44-6.
[A comparative study of the efficacy of Vermox, albendazole and medamine in an experimental model of trichocephaliasis in mice]

[Article in Russian]

Rashid VM.

A comparison of the efficacy of albendazole, medamine, and Vermox using an experimental model of Trichocephalus muris in DBA-2 mice showed that Vermox was most effective at all stages of the parasite development. The therapeutic activity of albendazole and medamine depends on daily dose, its dividing through the day and the duration of the treatment. At larval stages of T. muris complete recovery might be achieved using a daily dose of 25 mg/kg for albendazole and 150 mg/kg for medamine, but at the adult stage the doses of the drugs should be 3-4 times higher to achieve 100% effect. The resistance of T. muris to the drugs especially increases at the beginning of egg production.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1758364&dopt=Abstract albendazole Albenza